These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1006321)

  • 41. Discovery of a natural spirolactone derivative in man and animal.
    Genard P; Palem-Vliers M; Lomba-Pignon MR; Christiaens L; De Graeve J
    Arch Int Physiol Biochim; 1985 Sep; 93(3):255-6. PubMed ID: 2416293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The metabolism and biopharmaceutics of spironolactone in man.
    Overdiek HW; Merkus FW
    Rev Drug Metab Drug Interact; 1987; 5(4):273-302. PubMed ID: 3333882
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tissue distribution of 3H-canrenoate potassium in rabbits.
    Finn AM; Brown R; Sadée W
    J Pharm Sci; 1977 Feb; 66(2):275-7. PubMed ID: 839430
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 46. Glutathione conjugation of synthetic steroids in isolated rat hepatocytes.
    Higaki J; Matsui T; Ikenishi Y; Hirata M
    Steroids; 1989 Sep; 54(3):345-54. PubMed ID: 2588308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
    Sandall JM; Millership JS; Collier PS; McElnay JC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elimination of canrenone in congestive heart failure and chronic liver disease.
    Jackson L; Branch R; Levine D; Ramsay L
    Eur J Clin Pharmacol; 1977 Mar; 11(3):177-9. PubMed ID: 852495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The bioavailability of spironolactone hydrochlorothiazide combination preparation.
    Rameis H; Hitzenberger G; Horwatitsch H
    Int J Clin Pharmacol Ther Toxicol; 1982 Jul; 20(7):327-33. PubMed ID: 7107086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of single and divided daily dose spironolactone in the control of hypertension.
    Bell GM; Fananapazir L; Anderton JL
    Br J Clin Pharmacol; 1981 Oct; 12(4):585-8. PubMed ID: 7295494
    [No Abstract]   [Full Text] [Related]  

  • 51. Pharmacokinetics of spironolactone and potassium canrenoate in humans.
    Kojima K; Yamamoto K; Fujioka H; Kaneko H
    J Pharmacobiodyn; 1985 Mar; 8(3):161-6. PubMed ID: 4009408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simple gas chromatographic method with flame ionization detection for the determination of aldadiene in human urine.
    Fehér T; Bodrogi L; Váradi A
    J Chromatogr; 1976 Aug; 123(2):460-2. PubMed ID: 956316
    [No Abstract]   [Full Text] [Related]  

  • 53. [Relative bioavailability of a new spironolactone preparation (author's transl)].
    Erking W; Lücker PW; Stöcker KP; Wetzelsberger K
    Arzneimittelforschung; 1979; 29(8):1184-9. PubMed ID: 583021
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of short term canrenone treatment in idiopathic hirsutism.
    Sobbrio GA; Granata A; Panacea A; Trimarchi F
    Minerva Endocrinol; 1989; 14(2):105-8. PubMed ID: 2761494
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antagonism of fludrocortisone by spironolactone and canrenone.
    Huston GJ; Turner P
    Br J Clin Pharmacol; 1976 Feb; 3(1):201-4. PubMed ID: 973942
    [No Abstract]   [Full Text] [Related]  

  • 57. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk.
    Phelps DL; Karim A
    J Pharm Sci; 1977 Aug; 66(8):1203. PubMed ID: 894512
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proceedings: Acute and chronic effects of the aldosterone antagonist spironolactone and its main metabolite canrenone on plasma aldosterone concentration, plasma renin activity, serum electrolytes and on the excretion of aldosterone, fluid and electrolytes in rats.
    Erbler HC; Hilfenhaus M
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R52. PubMed ID: 1143449
    [No Abstract]   [Full Text] [Related]  

  • 59. Do canrenone and 6,7-dihydroxylated derivatives compete with ouabain at the same site on Na,K-ATPase?
    Tal DM; Karlish SJ
    Mol Pharmacol; 1988 Sep; 34(3):245-9. PubMed ID: 2843743
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis.
    Radó JP; Sawinsky I; Juhos E
    Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):163-7. PubMed ID: 1002353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.